Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine ...

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...

Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...

CHICAGO — June 5, 2017 — For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life ...

SWOG Clinical Trials Partnerships (SWOG CTP) has signed a collaborative research agreement with Novartis Pharmaceuticals Corporation to form a strategic alliance via our Preferred Partnership Program ...

The Lancet study shows addition of bortezomib significantly improves survival in treatment-naïve patients with multiple myeloma. In treatment-naïve patients with multiple myeloma, including ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added toxicity MOUNTAIN VIEW, Calif., January 08, 2026--(BUSINESS WIRE)--Osel Inc., a ...

SWOG Cancer Research Network and its charity, The Hope Foundation for Cancer Research, announce the award of two grants designed to give military veterans better access to cancer clinical trials.

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...